Novel Treatment for Osteoarthritis Using Imatinib Mesylate ID: 2017-015

A groundbreaking treatment for osteoarthritis, leveraging the cancer drug imatinib mesylate to inhibit the progression of the disease.

Technology Overview

This invention introduces a novel approach to treating osteoarthritis (OA) by using imatinib mesylate, a drug primarily used for cancer therapy, to block the activity of the DDR2 protein, which plays a crucial role in the progression of OA. By inhibiting DDR2 activation, imatinib mesylate aims to prevent joint degradation, offering a potential solution to halt or significantly slow down the disease's progression. The method suggests various administration routes, including topical and systemic, marking a significant innovation in OA treatment strategies.

Key Advantages

• Halts or slows down the progression of osteoarthritis, potentially delaying or eliminating the need for joint replacement
• Utilizes imatinib mesylate, a drug with a proven track record in cancer treatment, for a new application in treating OA
• Offers multiple administration routes, including less invasive options like topical application
• Supported by pilot proof of concept studies demonstrating efficacy in mouse models

Problems Addressed

• Provides a treatment option for osteoarthritis that goes beyond symptom management to address the underlying disease progression
• Offers a potential alternative to joint replacement surgery, reducing the economic and personal burden associated with OA

Market Applications

• Pharmaceutical development for OA treatment
• Non-invasive treatment options for early to mid-stage osteoarthritis patients
• Comprehensive OA management programs, integrating novel pharmacological approaches

Additional Information

Technology ID: 2017-015
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025